Literature DB >> 9417915

Cloning and genomic organization of the human transforming growth factor-beta type I receptor gene.

V F Vellucci1, M Reiss.   

Abstract

Transforming growth factor-beta (TGF beta) regulates cell cycle progression by a unique signaling mechanism that involves its binding to the type II (T beta R-II) TGF beta receptor and activation of type I (T beta R-I). Both are transmembrane serine-threonine receptor kinases. As various types of human tumor cells are often refractory to TGF beta-mediated cell cycle arrest, it is likely that the T beta R-I receptor is inactivated in many of these cases. We determined the intron-exon organization of the TGFBR1 gene. We report here that this gene is approximately 31 kb in length and consists of nine exons. The organization of the segment of the TGFBR1 gene that encodes the C-terminal portion of the serine-threonine kinase domain appears to be highly conserved between members of the R-I gene family. This information should facilitate and expedite the structural analysis of TGFBR1 in human tumors and possibly other disease states.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9417915     DOI: 10.1006/geno.1997.5023

Source DB:  PubMed          Journal:  Genomics        ISSN: 0888-7543            Impact factor:   5.736


  10 in total

1.  Brachydactyly type B: clinical description, genetic mapping to chromosome 9q, and evidence for a shared ancestral mutation.

Authors:  Y Gong; D Chitayat; B Kerr; T Chen; R Babul-Hirji; A Pal; M Reiss; M L Warman
Journal:  Am J Hum Genet       Date:  1999-02       Impact factor: 11.025

Review 2.  TGFBR1 signaling and breast cancer.

Authors:  Lakisha Moore-Smith; Boris Pasche
Journal:  J Mammary Gland Biol Neoplasia       Date:  2011-04-05       Impact factor: 2.673

3.  Species-specific sensitivity to TGFβ signaling and changes to the Mmp13 promoter underlie avian jaw development and evolution.

Authors:  Spenser S Smith; Daniel Chu; Tiange Qu; Jessye A Aggleton; Richard A Schneider
Journal:  Elife       Date:  2022-06-06       Impact factor: 8.713

4.  Mechanisms of decreased expression of transforming growth factor-beta receptor type I at late stages of HPV16-mediated transformation.

Authors:  Melissa K Hypes; Lucia Pirisi; Kim E Creek
Journal:  Cancer Lett       Date:  2009-04-02       Impact factor: 8.679

5.  Novel Ex Vivo Culture Method for the Study of Dupuytren's Disease: Effects of TGFβ Type 1 Receptor Modulation by Antisense Oligonucleotides.

Authors:  Sofia Karkampouna; Boudewijn Pt Kruithof; Peter Kloen; Miryam C Obdeijn; Annelies Ma van der Laan; Hans J Tanke; Dwi U Kemaladewi; Willem Mh Hoogaars; Peter Ac 't Hoen; Annemieke Aartsma-Rus; Ian M Clark; Peter Ten Dijke; Marie-José Goumans; Marianna Kruithof-de Julio
Journal:  Mol Ther Nucleic Acids       Date:  2014-01-21       Impact factor: 10.183

6.  Analysis of superoxide dismutase 1, dual-specificity phosphatase 1, and transforming growth factor, beta 1 genes expression in keratoconic and non-keratoconic corneas.

Authors:  Samira Saee-Rad; Reza Raoofian; Mirgholamreza Mahbod; Mohammad Miraftab; Majid Mojarrad; Soheila Asgari; Farhad Rezvan; Hassan Hashemi
Journal:  Mol Vis       Date:  2013-12-08       Impact factor: 2.367

7.  Two target regions of allelic loss on chromosome 9 in urinary-bladder cancer.

Authors:  K Ohgaki; K Minobe; K Kurose; A Iida; T Habuchi; O Ogawa; Y Kubota; M Akimoto; M Emi
Journal:  Jpn J Cancer Res       Date:  1999-09

8.  Molecular characterization of TGF-β type I receptor gene (Tgfbr1) in Chlamys farreri, and the association of allelic variants with growth traits.

Authors:  Huihui Guo; Zhenmin Bao; Jiqin Li; Shanshan Lian; Shi Wang; Yan He; Xiaoteng Fu; Lingling Zhang; Xiaoli Hu
Journal:  PLoS One       Date:  2012-11-29       Impact factor: 3.240

9.  Characterization of novel transforming growth factor-beta type I receptors found in malignant pleural effusion tumor cells.

Authors:  Kuo-Li Chen; Wan-Hsin Liu; Yi-Yuan Yang; Sy-Jye C Leu; Neng-Yao Shih
Journal:  BMC Mol Biol       Date:  2007-08-17       Impact factor: 2.946

10.  The Combinational Use of CRISPR/Cas9 and Targeted Toxin Technology Enables Efficient Isolation of Bi-Allelic Knockout Non-Human Mammalian Clones.

Authors:  Satoshi Watanabe; Takayuki Sakurai; Shingo Nakamura; Kazuchika Miyoshi; Masahiro Sato
Journal:  Int J Mol Sci       Date:  2018-04-04       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.